who should not take glp 1 receptor agonists Mapping the effectiveness and risks of GLP-1 The GLP-1 Agonists and Obesity:
Description
doi: 10.1161/hypertensionaha.120.14868 96 BharuchaAECharkoudianNAndrewsCNCamilleriMSlettenDZinsmeisterARet al
Download the guide or review the infographic below.
77 A meta-analysis of 76 RCTs, involving over 100,000 adults with overweight, obesity, or type 2 diabetes found that GLP-1 RA treatment, compared to placebo or other active comparators, was associated with a modestly elevated risk of cholelithiasis (RR: 1.27, 95% CI 1.10, 1.47), cholecystitis (RR: 1.36, 95% CI 1.14, 1.62), and overall biliary disease (RR: 1.55, 95% CI 1.08, 2.22), corresponding to an absolute increase of approximately 27 events per 10,000 patients per year
Will the oral GLP-1 pill be safe long-term
The enrollment process was simple and the team walked me through every step John C I joined MDWatch at the end of December 2025 after finding them online and completing a simple form with my Medicare information
